

<b>P.3</b>	<b>ALL RECOMMENDATIONS</b> (continued from P.2)
<b>Changes to Address Adverse Effects</b> <i>continued</i>	
<ul style="list-style-type: none"> <li>– Account for potential drug–drug interactions with chronically used concomitant medications, including nonprescription and over–the–counter medications, especially when switching from or to a regimen that may induce or inhibit shared metabolic pathways.</li> <li>– Minimize the potential for negative effects of a new ART regimen on any underlying chronic medical conditions, such as cardiovascular disease or risk, impaired renal function, or chronic anemia.</li> <li>– If a patient has chronic HBV infection, the clinician should include TAF/TDF in conjunction with 3TC/FTC or another agent with activity against HBV (e.g., ETV) in the patient's ART regimen. (A2)</li> </ul>	
<b>Changes to Address Drug–Drug Interactions</b>	
<ul style="list-style-type: none"> <li>– When changing a patient's ART regimen to address drug–drug interactions, the clinician should (A2): <ul style="list-style-type: none"> <li>– Acquire a current list of all medications that a patient is taking or any medications planned for treatment of a comorbid condition before constructing an ART regimen.</li> <li>– Account for the drug–clearance mechanisms and pharmacokinetic drug–drug interactions of ARVs to select optimal regimens.</li> <li>– Pay particular attention to the effect of starting or stopping specific ARVs, such as COBI or RTV, on concurrent medications that may require dose adjustment.</li> </ul> </li> </ul>	
<b>Changes Due to Pregnancy</b>	
<ul style="list-style-type: none"> <li>– When changing an ART regimen for a patient who is pregnant or planning pregnancy, the clinician should follow the recommendations in DHHS Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. (A3)</li> </ul>	
<b>Changes for Regimen Simplification</b>	
<ul style="list-style-type: none"> <li>– Clinicians should not prescribe single–agent ART. (A1)</li> <li>– When changing an ART regimen for simplification, i.e., to improve adherence, reduce cost, improve quality of life, or respond to a patient's request, clinicians should construct a new regimen based on an assessment of: <ul style="list-style-type: none"> <li>– History of ART failure (A2)</li> <li>– Evidence of clinical effectiveness (A2)</li> <li>– Tolerability (A2)</li> </ul> </li> <li>– Regardless of their viral suppression status, if a patient has ongoing adherence challenges with oral ART (even with support) and a CD4 count &lt;200 cells/mm<sup>3</sup> or intensified follow–up support. (A2) For clinical recommendations, see the NYSDOH AI guideline Use of Injectable CAB/RPV LA as Replacement ART in Virologically Suppressed Adults.</li> </ul>	
<i>Continued on P.4</i>	

<b>P.2</b>	<b>ALL RECOMMENDATIONS</b> (continued from P.1)
<b>Changes to Address Drug Resistance</b>	
<ul style="list-style-type: none"> <li>– When choosing a new ART regimen for a patient with drug–resistant virus, clinicians should: <ul style="list-style-type: none"> <li>– Choose a regimen that is likely to fully suppress viral replication, even if it may require multi–tablet dosing. (A1)</li> <li>– Document and evaluate the importance of all RAMs and identify the most tolerable regimen to suppress drug–resistant HIV effectively. (A3)</li> <li>– Clinicians should address barriers to ART adherence that may have contributed to failure of a patient's first–line regimen. (A2)</li> <li>– In constructing a new regimen to replace a failed ART regimen, the clinician should: <ul style="list-style-type: none"> <li>– Review all prior genotype or phenotype resistance assay results that are retrievable and previous instances of virologic treatment failure to assist in identifying potentially active medications. (A2)</li> <li>– Select agents to which the patient is naive or active second–generation agents with a previously prescribed class to avoid potential within–class cross–resistance. (A2)</li> </ul> </li> <li>– Select a regimen containing an agent with a high barrier to resistance, such as DRV, DTG, or BIC, if the M184V RAM is present and FTC/3TC will be used in conjunction with TAF/TDF. (A*)</li> <li>– Avoid monotherapy (i.e., an ART regimen with fewer than 2 fully active agents). (A1)</li> <li>– Choose the equivalent of 3 fully active ARVs; a 2–drug regimen may be prescribed when both are fully active and at least 1 is an agent with a high resistance barrier, i.e., a boosted PI or a second–generation INSTI. (A2)</li> <li>– Consult with an experienced HIV care provider when planning treatment regimens for patients with multidrug–resistant virus. (A3)</li> <li>– If a patient has chronic HBV infection, include TAF/TDF in conjunction with 3TC/FTC or another agent with activity against HBV (e.g., ETV) in the patient's ART regimen. (A2)</li> </ul> </li> </ul>	
<b>Changes to Address Adverse Effects</b>	
<ul style="list-style-type: none"> <li>– Clinicians should closely monitor the patient's response to ART by obtaining an HIV RNA test within 4 weeks of a change in regimen and at least every 8 weeks thereafter until virologic suppression is achieved. (A3)</li> <li>– When changing a patient's ART regimen to address adverse effects, the clinician should (A2): <ul style="list-style-type: none"> <li>– Review all prior genotype and phenotype resistance test results and ART history for evidence of virologic failure to inform the choice of a fully active regimen when switching from a suppressive regimen.</li> <li>– Account for the adverse effect profiles of ARVs, including cross–class toxicities.</li> </ul> </li> </ul>	
<i>Continued from P.1</i>	

<b>P.4</b>	<b>ALL RECOMMENDATIONS</b> (continued from P.3)
<b>Resumption of ART After Treatment Interruption</b>	
<ul style="list-style-type: none"> <li>– Although drug resistance may not be present in all cases, when reinitiating ART after an interruption, clinicians should identify factors that may have contributed to potential selection of drug resistance, including: <ul style="list-style-type: none"> <li>– Reason for a treatment interruption, i.e., strategic or unplanned (A3)</li> <li>– The patient's plasma HIV–1 RNA level (viral load) at the time of ART interruption (A2)</li> <li>– Duration of the interruption, particularly if agents with long clearance half–lives are being used (A2)</li> <li>– Pattern of adherence prior to discontinuation (A2)</li> <li>– Existence of any barriers to adherence before the treatment interruption and whether they are still present (A2)</li> </ul> </li> <li>– If the factor(s) related to interruption confer a low likelihood of emergent resistance, the clinician should recommend resumption of the previously tolerated ART regimen as soon as possible. (A2)</li> <li>– If the factor(s) related to interruption confer a high likelihood of emergent resistance, the clinician should recommend an appropriate ART regimen (based on assessment above) as soon as possible, with subsequent adjustment based on review of resistance test results. (A2)</li> <li>– If a patient had a detectable viral load before a treatment interruption of &lt;4 weeks, the clinician should obtain a plasma genotypic resistance test as soon as possible. (A2)</li> </ul>	

<b>P.4</b>	<b>ALL RECOMMENDATIONS</b> (continued from P.3)
<b>SELECTED KEY POINTS</b>	
<ul style="list-style-type: none"> <li>– Virologic failure is defined as a confirmed HIV viral load <math>\geq 200</math> copies/mL despite a patient's use of recommended ART for at least 24 weeks or an HIV viral load that rebounds to <math>\geq 200</math> copies/mL after a patient achieves viral suppression.</li> <li>– Persistent low–level viremia (HIV RNA 50 to 199 copies/mL) confirmed over a period of at least 1 month may be the cause or result of chronic immune activation and should prompt a clinician to assess for adherence, preexisting resistance, or drug–drug interactions.</li> <li>– Once underlying drug resistance, potential drug–drug interactions, and adherence have been addressed, persistent low–level viremia may reflect a large viral reservoir size or the consequence of constitutive, post–integration virus production from a single infected clone.</li> <li>– Identifying and addressing adherence problems causing virologic failure can prevent unnecessary ART intensification. Treatment intensification can further complicate adherence and expose additional classes of ARVs to the risk of resistance development.</li> <li>– Addition or removal of pharmacokinetic “boosters” or “inducers” can cause adverse effects associated with elevated exposure or withdrawal of concomitant medication. These adverse effects may be falsely attributed to a new ART regimen rather than the need for dose adjustment or modification of the coadministered medication.</li> </ul>	

<b>HIV CLINICAL RESOURCE</b> <b>1/4-FOLDED GUIDE</b>	
VISIT <a href="http://HIVGUIDELINES.ORG">HIVGUIDELINES.ORG</a> TO LEARN MORE OR VIEW COMPLETE GUIDE	
	<b>SECOND-LINE ART AFTER TREATMENT FAILURE OR FOR REGIMEN SIMPLIFICATION</b>
NYSDOH AIDS INSTITUTE HIV CLINICAL GUIDELINE <span style="float: right;">MARCH 2025</span>	
<b>P.1</b>	<b>ALL RECOMMENDATIONS</b>
<b>Identifying and Managing Virologic Failure</b>	
<ul style="list-style-type: none"> <li>– When a patient's plasma HIV–1 RNA level (viral load) is not suppressed to &lt;200 copies/mL by 24 weeks after ART initiation or if it rebounds to <math>\geq 200</math> copies/mL after suppression has been achieved, the clinician should confirm the result with a repeat HIV RNA test within 4 weeks of the original test. (A3)</li> <li>– When a patient's viral load test result indicates virologic failure (HIV RNA <math>\geq 200</math> copies/mL) or low–level viremia (HIV RNA 50 to 199 copies/mL) confirmed over a period of at least 1 month, the clinician should assess for and address the following factors that may reduce ART efficacy: <ul style="list-style-type: none"> <li>– Adherence (A2)</li> <li>– Interactions between ART agents and concomitant medications, including over–the–counter medications and supplements (e.g., divalent cations, St. John's wort) (A*)</li> <li>– Adverse effects that lead to poor adherence or cessation of treatment (A2)</li> <li>– Reviews of all prior drug resistance testing results, previous treatment experience, and reason for treatment changes or discontinuation (A3)</li> </ul> </li> <li>– For all cases of virologic failure, clinicians should perform genotypic resistance testing, ideally while the patient is taking the failing regimen or no longer than 4 weeks after discontinuation. (A2) <ul style="list-style-type: none"> <li>– If the viral load is <math>\geq 500</math> copies/mL, clinicians should obtain a plasma RNA genotype test. (A2)</li> <li>– If the breakthrough viral load is &lt;500 copies/mL, clinicians should obtain an archived DNA genotype test if viral suppression is not achieved after any drug–drug interactions or problems with adherence have been addressed. (B3)</li> </ul> </li> <li>– In patients with persistent low–level viremia, clinicians should consult an experienced HIV care provider; low–level viremia can have multiple causes and its clinical effect is unclear. (A3)</li> </ul>	
<i>Continued on P.2</i>	

Genotypic Resistance Testing Based on Viral Load	
HIV RNA Level (Viral Load)	Indicated Genotypic Resistance Test
0 to 500 copies/mL	HIV proviral DNA genotype (RT, PR, INT) or phenotype (tropism)
500 to 1,000 copies/mL	HIV RNA genotype (RT, PR, INT) or phenotype (tropism) at assay amplification threshold; may use HIV proviral DNA test if nonamplifiable
≥1,000 copies/mL	HIV RNA genotype if currently or recently (within 4 weeks) on ART; DNA proviral genotype may be considered for patients who are currently not taking ART but have in the past

ARVs by Level of Genetic Barrier to Resistance (for group M, subtype B HIV)		
Low Resistance (single mutation, common)	Intermediate Resistance (1 or 2 mutations, common)	High Resistance (>2 mutations, rarer)
<ul style="list-style-type: none"> <li>• 3TC</li> <li>• EFV</li> <li>• EVG</li> <li>• FTC</li> <li>• IBA</li> <li>• LEN</li> <li>• NVP</li> <li>• RAL</li> <li>• RPV</li> </ul>	<ul style="list-style-type: none"> <li>• ABC</li> <li>• CAB</li> <li>• DOR</li> <li>• FTR</li> <li>• TAF</li> <li>• TDF</li> <li>• ZDV</li> </ul>	<ul style="list-style-type: none"> <li>• ATV (with COBI or RTV)</li> <li>• BIC</li> <li>• DRV (with COBI or RTV)</li> <li>• DTG</li> <li>• ETR</li> <li>• MVC</li> </ul>

Types of HIV Resistance Tests (All resistance assays are affected by limitations of detection; minor variants may not be present at high enough concentrations to be amplified by the assay.)	
Test	Description and Use
Genotype	<ul style="list-style-type: none"> <li>• Assesses mutations in the HIV RNA genes that encode enzymes targeted by ARVs: RT, PR, INT</li> <li>• Algorithms interpret the effect of mutations on ARV efficacy</li> <li>• At diagnosis, when a patient has incomplete virologic response to ART, or when viral rebound occurs</li> <li>• Has utility if plasma HIV-1 RNA level (viral load) is ≥500 to 1,000 copies/mL</li> <li>• May not detect all RAMs</li> </ul>
Phenotype	<ul style="list-style-type: none"> <li>• Assesses the effect of HIV genes on the ARV concentration required to inhibit viral growth compared with wild-type (nonmutant) virus</li> <li>• Estimates a fold change</li> <li>• Historically used to help assess the effect of the interplay of multiple RAMs on viral growth</li> <li>• Supplanted by more comprehensive genotypic interpretation algorithms</li> </ul>
Provirial DNA genotype (archived genotype)	<ul style="list-style-type: none"> <li>• Assesses genetic mutations in HIV proviral DNA genes that encode enzymes targeted by ARVs: RT, PR, INT</li> <li>• Algorithms interpret the effect of mutations on ARV efficacy</li> <li>• When planning ART simplification or other changes, may have a role in identifying RAMs when standard genotype testing may not yield results, i.e., in patients who have prior treatment experience, have stopped taking ARVs for &gt;4 weeks, or have an HIV viral load &lt;500 to 1,000 copies/mL or below the limit of quantification</li> <li>• May not detect all RAMs in proviral DNA, or may report RAMs from non-replication-competent viruses</li> </ul>
Tropism test	<ul style="list-style-type: none"> <li>• Assesses the effect of HIV RNA (or proviral DNA) gp120 on the coreceptor(s) used for viral attachment: CCR5, CXCR4, or mixed/dual</li> <li>• Treatment-experienced patients for whom a coreceptor antagonist is being imminently considered</li> <li>• RNA tropism test can be used with viral loads ≥1,000 copies/mL; proviral DNA test can be used for viral loads &lt;1,000 copies/mL</li> </ul>

ART Options After First-Line Treatment Failure With Single-Class Drug Resistance [a,b]	
Failed First-Line Regimen Drug Classes	Classes and Medication Options for Switch
2 NRTIs + 1 NNRTI [a]	<ul style="list-style-type: none"> <li>• 2 NRTIs + 1 boosted PI:               <ul style="list-style-type: none"> <li>– TAF/FTC/DRV/COBI (single tablet)</li> <li>– TAF/FTC + DRV/RTV</li> </ul> </li> <li>• 2 NRTIs + 1 INSTI:               <ul style="list-style-type: none"> <li>– TAF/FTC/BIC (single tablet)</li> <li>– TAF/FTC + DTG</li> </ul> </li> </ul>
2 NRTIs + 1 PI [a]	<ul style="list-style-type: none"> <li>• 2 NRTIs + 1 INSTI:               <ul style="list-style-type: none"> <li>– TAF/FTC/DRV/COBI (single tablet)</li> <li>– TAF/FTC + DTG</li> </ul> </li> <li>• 1 INSTI + 1 NNRTI: RPV/DTG (single tablet)</li> <li>• 2 NRTIs + 1 fully active boosted PI</li> </ul>
2 NRTIs + 1 INSTI [a]	<ul style="list-style-type: none"> <li>• 2 NRTIs + 1 boosted PI:               <ul style="list-style-type: none"> <li>– TAF/FTC/DRV/COBI (single tablet)</li> <li>– TAF/FTC + DRV/RTV</li> </ul> </li> </ul>
Multiclass	<ul style="list-style-type: none"> <li>• 2 NRTIs + 1 INSTI + 1 boosted PI +/- 1 NNRTI (based on genotype):               <ul style="list-style-type: none"> <li>– Consider: MVC [c], FTR, IBA, LEN, ETR, DOR, RPV, TPV</li> </ul> </li> </ul>

**Notes:** a) Single-class resistance, with no major NRTI RAMs other than M184V. b) Consider use of the ARV selection tool HIV-ASSIST. c) If current tropism assay indicates exclusive R5 tropic virus.

Common Adverse Effects Associated With ARVs			
NRTIs	NNRTIs	PIs	INSTIs
<ul style="list-style-type: none"> <li>• <b>ABC</b> [a]: Cardiovascular disease; hypersensitivity</li> <li>• <b>DDI, d4T, ZDV</b>: Mitochondrial toxicity; lipodystrophy; lactic acidosis</li> <li>• <b>TAF</b>: Weight gain; increased lipids</li> <li>• <b>TDF</b>: Proximal renal tubule injury; decrease in bone mineral density</li> </ul>	<ul style="list-style-type: none"> <li>• <b>DOR</b>: CNS effects</li> <li>• <b>EFV</b>: Hepato-toxicity; vitamin D deficiency; CNS effects; skin reactions; depression; morning somnolence</li> <li>• <b>NVP</b>: Hepato-toxicity; hypersensitivity</li> <li>• <b>RPV</b>: CNS effects; skin reactions; effects on the measure of eGFR</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Class effect</b> [b]: Increased cholesterol [c]; increased triglycerides [c]; increased glucose, lipodystrophy</li> <li>• <b>ATV</b>: Nephro-lithiasis; renal insufficiency; hyperbilirubinemia</li> <li>• <b>DRV</b>: Cardiovascular disease; skin reactions</li> <li>• <b>LPV/RTV</b>: Cardiovascular disease</li> </ul>	<ul style="list-style-type: none"> <li>• <b>Class effect</b> [b]: Weight gain</li> <li>• <b>BIC</b>: Effects on the measure of eGFR</li> <li>• <b>DTG</b>: CNS effects; effects on the measure of eGFR</li> <li>• <b>EVG/COBI</b>: Increased lipids; effects on the measure of eGFR</li> </ul>

**Notes:** a) Screen to document that the patient is negative for HLA-B\*5701 before use. b) Adverse effects apply to all drugs in this class. c) Especially with RTV and COBI pharmacoenhancement.

**Abbreviations:** 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; ARV, antiretroviral medication; ATV, atazanavir; BIC, bictegravir; CAB, cabotegravir; CAB/RPV LA, long-acting cabotegravir and rilpivirine; CNS, central nervous system; COBI, cobicistat; d4T, stavudine; DDI, didanosine; DHHS, U.S. Department of Health and Human Services; DOR, doravirine; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; eGFR, estimated glomerular filtration rate; ETR, etravirine; ETV, entecavir; EVG, elvitegravir; FTC, emtricitabine; FTR, fostemsavir; gp120, envelope glycoprotein 120; HBV, hepatitis B virus; IBA, ibalizumab; INSTI, integrase strand transfer inhibitor; INT, integrase; LEN, lenacapavir; LPV, lopinavir; MVC, maraviroc; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside/nucleotide reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; PR, protease; RAL, raltegravir; RAM, resistance-associated mutation; RPV, rilpivirine; RT, reverse transcriptase; RTV, ritonavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; TPV, tipranavir; ZDV, zidovudine.



← Use this code with your phone's QR code reader to go directly to a mobile-friendly version of the guideline.

■ This 1/4-Folded Guide is a companion to the New York State Department of Health AIDS Institute guideline *Second-Line ART After Treatment Failure or for Regimen Simplification*. The full guideline is available at [www.hivguidelines.org](http://www.hivguidelines.org).